In this piece, we will look at the stocks Jim Cramer recently discussed.
In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer discussed the latest figures for GDP growth. The Commerce Department’s GDP data for the third quarter showed that the economy grew by 4.3% in the September quarter. The growth figure sharply exceeded economists’ expectations of a 3.2% growth. A key factor in the data was consumer spending which which grew at 3.5% which was the fastest pace in the year. Crucially, in his morning appearance on December 19th, the CNBC TV host had countered a pessimistic report by Bank of America by remarking that he believed consumer spending would be “much stronger.” As the data hit the wires, Cramer commented:
“Right, now we’ve got a couple of things going. First of all, it’s backward, it’s not forward. Second, I think that there are people who recognize that we have a bifurcated economy. The rich people are spending like crazy, the people who are less well off, are holding back. So the GDP may not be necessarily be an indicator of the, of the health of the country as much as I typically think it is.”
Our Methodology
To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC’s Squawk on the Street aired on December 23rd. We also provided hedge fund sentiment for each stock as of the third quarter of 2025, which was taken from Insider Monkey’s database of 978 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
10. Novo Nordisk A/S (NYSE:NVO)
Number of Hedge Fund Holdings: 50
Danish pharmaceutical firm Novo Nordisk A/S (NYSE:NVO) scored a major win earlier this month after it secured the Food and Drug Administration’s (FDA) approval for its weight loss pill. The approval made the Wegovy pill the first of its kind, and it led to the firm’s shares closing 7.30% higher. The approval marked a key win for Novo Nordisk A/S (NYSE:NVO) as the firm has reportedly struggled against Eli Lilly in the weight loss drug market. Following the Wegovy pill approval, the pharmaceutical company moved fast, as a report from the Chinese outlet Yicai suggested that Novo Nordisk A/S (NYSE:NVO) had cut the prices of its highest dosage Wegovy drugs in half in some Chinese provinces. After the approval, BMO Capital reiterated a Market Perform rating and a $46 share price target for the company. The financial firm outlined that Novo Nordisk A/S (NYSE:NVO) could benefit from a first-mover advantage in the oral weight loss drug market and added that it could face competitive challenges in the future. Cramer shared his own unique take on the matter, as he commented that Novo Nordisk A/S (NYSE:NVO) might see resistance from physicians when it comes to taking away market share from Eli Lilly:
“Now, remember, that a pill is much preferred in the country, versus the shot. If you are taking Wegovy, then people will move over, quickly migrate over to Wegovy pill. . .let’s say you are taking Mounjaro right now, Eli Lilly, they are reluctant to say listen you should go do Wegovy. Because what they’ll say is listen, you tolerate Mounjaro, and we just care about toleration. And that’s been the way things go. And I think people who think, wow, there are people who are going to be really excited to move over to the pill. Their advice from the doctors is going to be, no, there could be different reactions. And apparently the doses are so high, that there are some different changes in diet that you might have to do. We don’t know enough about what the side effects are, we know this. The profession just doesn’t like you to switch from one drug to another.
“I think that there are a lot of people who are scared to give themselves a shot. A lot of people who think the shot hurts. You have to take the shot every once a week. So I think, yeah it’s a big win, I didn’t see it, my charitable trust owns Eli Lilly, and I think three months from now we say, okay, Lilly’s in the market but, last night I’m doing Mad Money and I’m saying, oh jeez, this isn’t supposed to happen. Because I didn’t want to see, I knew that for our trust that Eli Lilly would be down, I don’t think it should be down . . .
“Anytime you have to put something in cold, although once you take it out,a lot of these drugs, once you take it out, you’re okay, but you gotta keep it refrigerated. People don’t like that. People really have a shorter term. . .people stop after 13 months, on the shot, they just don’t like it. And this is going to be much longer. That’s something David Ricks has talked about, the CEO of Lilly. He’s told me, when he’s come on Mad Money, don’t forget, the people just, they stop taking it. And one of the reasons they stop taking it, is because, wow I don’t want to take a shot anymore. And they also say, listen I’m thin, so I’m fine. Completely untrue, these are lifetime drugs.”
9. ServiceNow, Inc. (NYSE:NOW)
Number of Hedge Fund Holdings: 104
Enterprise workflow management software services provider ServiceNow, Inc. (NYSE:NOW) announced an important deal the day this show was aired, as it announced that it would acquire cybersecurity firm Armis for a $7.5 billion price tag. Throughout 2025, Cramer has maintained that the cybersecurity sector continues to be attractive in the broader software industry as it benefits from national security tailwinds and the growth in data usage stemming from AI. Earlier in the month, Bernstein had maintained a $1,093 share price target for ServiceNow, Inc. (NYSE:NOW) and assigned an Overweight rating to the shares. As reports of the merger made rounds in markets ahead of the official announcement and led to weakness in the shares, the financial firm commented that channel checks indicated demand acceleration and the selloff hinted at undervaluation. After the deal was announced, Cramer was unsurprisingly optimistic, given his thoughts surrounding the cybersecurity sector:
“No, and this is very important, because, ServiceNow, is in many ways, very important within the organization. Whenever they get in, but they haven’t been strong in something that everybody wants, which is cybersecurity. And this is, I think, integral to the suite, to a platform that you have. ServiceNow going beyond, just a vertical of IT and going to a platform. That’s what everybody is doing. And I think it’ll be important, because the compression of the price-to-earnings multiple for ServiceNow is huge.”
Hedge Fund Resource Center